Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H19N3O3S.C6H12O7 |
| Molecular Weight | 589.614 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.COC1=CC(NS(C)(=O)=O)=CC=C1NC2=C3C=CC=CC3=NC4=CC=CC=C24
InChI
InChIKey=XXNAQBNJPZNRSZ-IFWQJVLJSA-N
InChI=1S/C21H19N3O3S.C6H12O7/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21;7-1-2(8)3(9)4(10)5(11)6(12)13/h3-13,24H,1-2H3,(H,22,23);2-5,7-11H,1H2,(H,12,13)/t;2-,3-,4+,5-/m.1/s1
| Molecular Formula | C21H19N3O3S |
| Molecular Weight | 393.459 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H12O7 |
| Molecular Weight | 196.1553 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6580948Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/3884748 | https://www.ncbi.nlm.nih.gov/pubmed/2752503
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6580948
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/3884748 | https://www.ncbi.nlm.nih.gov/pubmed/2752503
The gluconate formulation of amsacrine (AMSA) has better water solubility then DMA formulation. It was thus developed and investigated to determine if it would be less cardiotoxic than the widely used N,N-dimethylacetamide (DMA) formulation. Amsacrine gluconate is the anticancer agent, which was tested against refractory leukemia. Moreover, their cytotoxic activity was demonstrated in the in vitro studies on 48 specimens of 9 histologically different types of human malignancy. The use of the gluconate formulation of AMSA, which contains no dimethylacetamide, has been associated with three cases of cardiomyopathy. Also, paresthesia was found in one patient among 26 treated with AMSA gluconate. This preparation has no apparent advantage when compared with amsacrine lactate.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1177257
Curator's Comment: Amsacrine preparation
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2602146 |
|||
Target ID: CHEMBL1806 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10691026 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6580948
120 mg/m2 daily for 5 days
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2752503
A total of 128 human tumors were placed in culture and tested against amsacrine. At 10 ug/ml amsacrine gluconate showed cytotoxic activity against breast, colon, and lung cancer as well as melanoma with an overall activity of 37%.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:17 GMT 2025
by
admin
on
Mon Mar 31 18:00:17 GMT 2025
|
| Record UNII |
M4P91439UZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
22824017
Created by
admin on Mon Mar 31 18:00:17 GMT 2025 , Edited by admin on Mon Mar 31 18:00:17 GMT 2025
|
PRIMARY | |||
|
80277-07-2
Created by
admin on Mon Mar 31 18:00:17 GMT 2025 , Edited by admin on Mon Mar 31 18:00:17 GMT 2025
|
PRIMARY | |||
|
334213
Created by
admin on Mon Mar 31 18:00:17 GMT 2025 , Edited by admin on Mon Mar 31 18:00:17 GMT 2025
|
PRIMARY | |||
|
M4P91439UZ
Created by
admin on Mon Mar 31 18:00:17 GMT 2025 , Edited by admin on Mon Mar 31 18:00:17 GMT 2025
|
PRIMARY | |||
|
DTXSID001001136
Created by
admin on Mon Mar 31 18:00:17 GMT 2025 , Edited by admin on Mon Mar 31 18:00:17 GMT 2025
|
PRIMARY | |||
|
DBSALT002301
Created by
admin on Mon Mar 31 18:00:17 GMT 2025 , Edited by admin on Mon Mar 31 18:00:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
|